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Antibiotic resistanceAbstract Background: Information regarding acute otitis media (AOM) aetiology is
important for developing effective vaccines. Here, bacterial aetiology and antimi-
crobial susceptibility of AOM were determined in young Saudi children.
Methods: Children aged 3–60 months with a new episode of AOM, who had not
received antibiotics or had received antibiotics for 48–72 h but remained symptom-
atic, were enrolled in this prospective, observational, epidemiological study in
Riyadh. Middle ear fluid (MEF) samples were collected by tympanocentesis or from
spontaneous otorrhea, and tested for the presence of Streptococcus pneumoniae,
Haemophilus influenzae, Streptococcus pyogenes and Moraxella catarrhalis.
Antimicrobial susceptibility of the identified pathogens was assessed using E-tests.
232 K.A. Al-Mazrou et al.Results: Between June 2009 and May 2011, 66 children were enrolled. S. pneumo-
niae was detected in 6 episodes and non-typeable H. influenzae (NTHi) in 8
episodes. Moreover, Staphylococcus aureus, which is an uncommon cause of AOM,
was detected in 17 episodes. Pneumococcal serotypes were 7F (n = 2), 23F (n = 2),
19F (n = 1) and 15F (n = 1). Susceptibility to cefotaxime was observed in all
pneumococcal and H. influenzae isolates, to cefuroxime in 4/6 pneumococcal and
8/8 H. influenzae isolates, and to penicillin in 5/6 pneumococcal isolates.
Conclusions: S. pneumoniae and NTHi were major bacterial contributors for AOM
in Saudi children.
ª 2014 Published by Elsevier Ltd. on behalf of Ministry of Health, Saudi Arabia. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Acute otitis media (AOM) is one of the most com-
mon paediatric bacterial infections, affecting
approximately 80% of children by the age of 3 years
[1–3]. The main bacteria responsible for AOM in
children are Streptococcus pneumoniae, Haemoph-
ilus influenzae and, to a much lesser extent, Mor-
axella catarrhalis and Streptococcus pyogenes
[4,5]. Although previous studies suggested that
approximately 1% of children are diagnosed with
AOM in Saudi Arabia, those younger than 4 years
of age are more affected than older children, and
the incidence of paediatric AOM varies among the
different regions and geographic settings. There
is limited available information on the prevalence
and aetiology of AOM in Saudi Arabia [6,7].
AOM is one of the primary reasons for antibiotic
use in children, and inappropriate or extensive use
of antibiotics may lead to increasing resistance
among pathogens [1]. Multi-drug resistance in
S. pneumoniae is a major public health concern
in many countries across the world [8–10], includ-
ing Saudi Arabia, where a high and increasing
prevalence of antibiotic-resistant pneumococcal
isolates is observed [11]. In Saudi Arabia, primary
vaccination of infants and young children with
pneumococcal conjugate vaccines has been
included in the national Expanded Programme on
Immunization (EPI) since February 2009. Currently,
three pneumococcal conjugate vaccines are avail-
able, and the vaccination coverage rates reached
98% of Saudi toddlers younger than 1 year of age
in 2010 [12].
The present study was designed to determine the
aetiology of AOM in Saudi children, as well as the
antimicrobial susceptibility of the identified patho-
gens and the vaccination status of the children. Up-
to-date information regarding AOM aetiology is
important for developing and implementing effec-
tive vaccines in Saudi Arabia, especially since
previous studies suggested that changes in the dis-tribution of pathogens and pneumococcal serotypes
might occur after the introduction of pneumococcal
conjugate vaccines [13–17].
2. Methods
2.1. Study design, setting and participants
This prospective, observational, epidemiological
study was conducted in a routine clinical setting
in Saudi Arabia between June 2009 and May 2011.
One primary centre and several satellite centres,
belonging to the same primary centre administra-
tion and Institution Review Board in Riyadh, were
included in this study. Study participants were chil-
dren between 3 months and 5 years of age, diag-
nosed as having AOM, and from whom a middle
ear fluid (MEF) sample had been obtained by an
ear, nose and throat (ENT) specialist. MEF samples
were taken by tympanocentesis or by careful sam-
pling of spontaneous otorrhea if perforation had
occurred less than 24 h prior to the visit.
Children were eligible if they had at least one
sign of otalgia (or its equivalent: irritability), con-
junctivitis or fever, and either Paradises criteria
(bulging, diffused or localised inflamed tympanic
membranes) [18] or spontaneous otorrhea that
had occurred less than 24 h prior to the visit. More-
over, the onset of signs and symptoms of AOM had
to occur within 72 h prior to the diagnosis of AOM
by a physician. Children were excluded from the
study if they were hospitalised during the diagnosis
of AOM or during treatment; had otitis externa or
otitis media with effusion; had a tympanostomy
tube; received systemic antibiotic treatment for
a disease other than AOM in the 72 h prior to enrol-
ment; received antimicrobial prophylaxis for recur-
rent AOM; received antibiotics by the paediatrician
or ENT specialist at the enrolment visit prior to the
sampling of MEF or spontaneous otorrhea; or had
received antibiotics for AOM and were clinically
improving.
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of AOM who had not yet received antibiotic therapy
for the episode (untreated children), and children
who had a diagnosis of AOM within 48–72 h prior
to study enrolment, had received antibiotic ther-
apy from a physician and remained symptomatic
at the time of study entry (children with treatment
failure). Children were enrolled by one of the study
paediatricians or ENT specialists, and a child could
be enrolled for more than one AOM episode if there
was a symptom-free interval of at least 30 days
between episodes.
The study was conducted according to Good
Clinical Practice, the Declaration of Helsinki,
and the local rules and regulations of the country
[19]. Before enrolment, informed consent was
obtained from the parents/guardians of each
study participant. No fees for recruiting children
were given in this study. All study documents
and procedures were approved by the hospital
Institution Review Board and research commit-
tee, and the Saudi Food and Drug Administration
(FDA) was notified of this study as per Saudi
regulations.
2.2. Study objectives
The primary objective of this study was to identify
pathogens considered likely to be responsible for
AOM (S. pneumoniae, H. influenzae, S. pyogenes
and M. catarrhalis) in MEF samples from Saudi chil-
dren between 3 months and 5 years of age diag-
nosed with AOM.
The secondary objectives of this study included
the determination of (1) the serotypes of S. pneu-
moniae and H. influenzae responsible for AOM in
Saudi children; (2) the antimicrobial susceptibility
profiles of the isolated bacteria; (3) the proportion
of children with treatment failures, recurrent AOM
episodes (defined as at least 3 episodes in the last
6 months or at least 4 episodes in the last
12 months) and spontaneous otorrhea; and (4) the
proportion of H. influenzae isolates identified in
children who either received a pneumococcal con-
jugate vaccine or were unvaccinated against pneu-
mococcal diseases.
2.3. Study procedures
All the children presenting to one of the paediatri-
cians or ENT specialists with AOM were anony-
mously recorded in a screening logbook and
assessed for study eligibility. Demographic infor-
mation, pneumococcal vaccination status, medical
history, care history and general symptoms of the
enrolled children were recorded.After confirmation of the AOM diagnosis by an
ENT specialist, a MEF sample was taken by tympa-
nocentesis via passage of a sterile needle through
an intact tympanic membrane, or an otorrhea sam-
ple was collected after cleaning of the ear canal
and via deep aspiration of MEF material through
needle insertion in children with perforation of
the tympanic membrane that occurred less than
24 h prior to the visit. Throughout the entire study,
no serious adverse events related to tympanocen-
tesis were reported, showing that it is a safe proce-
dure. If possible, urine samples were also collected
from the enrolled children for antimicrobial activ-
ity testing.
2.4. Laboratory procedures
MEF samples were inoculated in chocolate agar
(otorrhea samples were inoculated in chocolate
agar with bacitracin to avoid mixed flora) and
blood agar (with gentamycin) at 35 ± 2 C in an aer-
obic atmosphere supplemented with CO2 [20]. Bac-
terial identification of the pathogens was made
using standard bacteriological procedures: S. pneu-
moniae was identified by Optochin and Bile salt
tests; H. influenzae identification was based on
Gram staining, growth on chocolate agar, failure
to grow on trypticase agar with added sheep blood,
and nutritional requirement of both hemin (Factor
X) and nicotine adenine dinucleotide (Factor V); S.
pyogenes identification was based on the presence
of b-haemolysis, susceptibility to bacitracin and
positive co-agglutination; and M. catarrhalis iden-
tification was based on Gram staining, positive oxi-
dase reaction and characteristic biochemical
profiling [20]. Staphylococcus aureus identification
was based on Gram staining, the presence of coag-
ulation and the use of DNA, and was confirmed
using Slides staph plus Kit (Bio Merieux) [20]. Pneu-
mococcal serotypes were identified by Quellung
reaction, and H. influenzae serotypes were identi-
fied using monovalent anti-sera.
In S. pneumoniae, H. influenzae, and M.
catarrhalis isolates, antimicrobial susceptibility to
penicillin, amoxicillin/clavulanate, cefuroxime,
cefotaxime, erythromycin, azithromycin, chloram-
phenicol, tetracycline, levofloxacin and trimetho-
prim/sulfamethoxazole were tested using E-tests
[21]. In H. influenzae and M. catarrhalis isolates,
antimicrobial susceptibility to ampicillin was also
assessed and a beta-lactamase test using a chromo-
genic cephalosporin (Nitrocefin) was performed
[20,22].
Antimicrobial activity was evaluated on urine
samples, using an antibacterial substance assay,
as previously described [23].
Table 1 Demographics and clinical history of children
experiencing episodes of acute otitis media (total
cohort).
Total number of episodes 66
Age (months)
Mean ± Standard deviation 24 ± 16
Range 3–58
Age category Number (percentage)
of episodes
3–11 months 15 (23%)
12–23 months 24 (36%)
24–35 months 14 (21%)
36–47 months 3 (5%)
48–59 months 10 (15%)
Gender Number (percentage)
of episodes
Female 27 (41%)
Male 39 (59%)
Pneumococcal vaccination
status
Number (percentage)
of episodes
Vaccinated 11 (17%)
Unvaccinated 11 (17%)
Unknown 44 (67%)
Collection methods Number (percentage)
of samples
Otorrhea 23 (31%)
Tympanocentesis 52 (69%)
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Since none of the enrolled children were elimi-
nated in this study, all analyses were performed
on the total cohort, which included all children
who met all eligibility criteria, complied with the
procedures defined in the protocol, had no
elimination criteria during the study and for whom
results for a MEF sample were available. All analy-
ses were descriptive, and results are presented in
terms of frequencies, proportions and 95% confi-
dence intervals (CI).
3. Results
3.1. Clinical and demographic
characteristics of enrolled children
Between June 2009 and May 2011, 246 children
with AOM were screened and 66 children were
enrolled in the study. Two children were enrolled
by a paediatrician and 64 children by an ENT spe-
cialist. A peak of enrolled children was observed
in January 2010 (11 screened and 9 enrolled chil-
dren), and there was also a peak of screened and
enrolled children in January 2011 (55 screened
and 13 enrolled children). Of the 66 enrolled chil-
dren, 62 were classified as untreated children and
4 as children with treatment failures. In the total
cohort, all children had experienced a single AOM
episode.
In the total cohort, 41% (27/66) of episodes were
reported in girls. The mean age of the children was
24 ± 16 months (range 3–58 months) and most of
the episodes (53/66 [80%]) were reported in chil-
dren younger than 36 months of age, with a peak
between 12 and 23 months (24/66 [36%]) (Table 1).
Eleven episodes (17%) were reported in children
who had been vaccinated with a pneumococcal
conjugate vaccine, 11 episodes (17%) in unvacci-
nated children and 44 episodes (67%) in children
with an unknown pneumococcal vaccination status.
Moreover, 12 episodes (18%) were reported in chil-
dren who had received at least one dose of H. influ-
enzae vaccine. Antibiotic use within the past
month was reported in 8% (5/66) of episodes.
However, no antimicrobial activity, indicating the
presence of antibiotic residuals or metabolites,
was detected by the antibacterial substance assay
performed on the 7 available urine samples (6 sam-
ples from episodes in untreated children and 1
sample from an episode in a child with treatment
failure).
None of the AOM episodes were recurrent,
according to the definition used in the study,and only 6/66 (9%) episodes were reported in
children with a history of AOM episodes in the
past 12 months. The most frequently reported
symptom was ear pain (59/66), followed by irri-
tability (29/66), fever (21/66), ear discharge
(20/66) and trouble sleeping (20/66). Among
the 66 AOM episodes, there were 10 bilateral
infections.
3.2. Microbiological aspects of samples
In this study, results were available for 75 MEF sam-
ples collected during the 66 AOM episodes; samples
from both the left and the right ears were available
for 9/10 children with a bilateral infection.
Among the 75 MEF samples, 23 were otorrhea sam-
ples and 52 were collected by tympanocentesis;
21% (14/66) of episodes and 20% (15/75) of MEF
samples were positive for one of the pathogens
under investigation. Among these positive epi-
sodes, 8/14 were identified in otorrhea samples
and 6/14 in samples collected by tympanocentesis.
Moreover, 12/14 positive episodes were identified
in untreated children and 2/14 in children with
treatment failure.
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lected during 6 episodes (the same S. pneumoniae
isolate was detected in 2 samples taken from the
same child, who had a bilateral infection), and
H. influenzae in 8 samples collected during 8 epi-
sodes. The 6 S. pneumoniae isolates were detected
in untreated children, and were identified as
serotypes 7F (n = 2), 23F (n = 2), 19F (n = 1) and
15F (n = 1). H. influenzae isolates were detected
in 2/4 children with treatment failure group and
in 6/62 untreated children. The 8 H. influenzae iso-
lates were non-typeable (NTHi).
All S. pneumoniae isolates were detected in chil-
dren with unknown pneumococcal vaccination sta-
tus. H. influenzae isolates were identified in 4/11
episodes reported in children who had been vacci-
nated with a pneumococcal conjugate vaccine and
in 4/44 episodes reported in children with an
unknown vaccination status. No H. influenzae iso-
lates were identified in episodes reported in unvac-
cinated children.Table 2 Antimicrobial susceptibility of S. pneumoniae and H
(total cohort).
Characteristics Categories or parameter
S. pneumoniae isolates (N = 6)
Penicillin Susceptible (MIC 6 2 lg/mL)
Amoxicillin/clavulanate Susceptible (MIC 6 2/1 lg/mL)
Cefuroxime Susceptible (MIC 6 0.5 lg/mL)
Cefotaxime Susceptible (MIC 6 1 lg/mL)
Erythromycin Susceptible (MIC 6 0.25 lg/mL
Azithromycin Susceptible (MIC 6 0.5 lg/mL)
Chloramphenicol Susceptible (MIC 6 4 lg/mL)
Tetracycline Susceptible (MIC 6 2 lg/mL)
Levofloxacin Susceptible (MIC 6 2 lg/mL)
TMP/sulfamethoxazole Susceptible (MIC 6 0.5/9.5 lg/
H. influenzae isolates (N = 8)
Penicillin MIC Mean
Standard deviation
Erythromycin MIC Mean
Standard deviation
Azithromycin MIC Mean
Standard deviation
Amoxicillin/clavulanate Susceptible (MIC 6 4/2 lg/mL)
Cefuroxime Susceptible (MIC 6 4 lg/mL)
Cefotaxime Susceptible (MIC 6 2 lg/mL)
Chloramphenicol Susceptible (MIC 6 2 lg/mL)
Tetracycline Susceptible (MIC 6 2 lg/mL)
Levofloxacin Susceptible (MIC 6 2 lg/mL)
TMP/sulfamethoxazole Susceptible (MIC 6 0.5/9.5 lg/
Ampicillin* Susceptible (MIC 6 1 lg/mL)
Nitrocefin Negative
Positive
N = total number of S. pneumoniae or H. influenzae isolates in
TMP = trimethoprim.
* Results for ampicillin were missing for one H. influenzae isolate,Beside the pathogens under study, other bacte-
ria were identified in 21/66 episodes and 24/75
MEF samples. Among the other bacteria, S. aureus
was the most common and was detected in 17/
21episodes; 9/17 S. aureus isolates were detected
in otorrhea samples and 8/17 in samples collected
by tympanocentesis.3.3. Antimicrobial susceptibility
Among the 6 S. pneumoniae isolates, all were
found to be susceptible to amoxicillin/clavulanate,
cefotaxime and levofloxacin; 5, to penicillin, azith-
romycin and chloramphenicol; 4, to cefuroxime,
erythromycin and tetracycline; and 3, to trimetho-
prim/sulfamethoxazole (Table 2). Two S. pneumo-
niae isolates were resistant to cefuroxime,
tetracycline and trimethoprim/sulfamethoxazole,
and 1, to erythromycin, azithromycin and
chloramphenicol.. influenzae isolated from children with acute otitis media
Number of isolates Percentage of isolates
5 83
6 100
4 67
6 100
) 4 67
5 83
5 83
4 67
6 100
mL) 3 50
16 –
14 –
4 –
2 –
3 –
1 –
7 88
8 100
8 100
7 88
6 75
8 100
mL) 0 0
1 14
2 25
6 75
a given category; MIC = minimum inhibitory concentration;
which was lost during storage.
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susceptible to cefuroxime, cefotaxime and
levofloxacin; 7, to amoxicillin/clavulanate and
chloramphenicol; 6, to tetracycline; and 1, to ampi-
cillin (Table 2). Five H. influenzae isolates were
resistant to ampicillin; 3, to trimethoprim/sulfa-
methoxazole; and 1, to amoxicillin/clavulanate
and chloramphenicol. The Nitrocefin test (beta-lac-
tamase test) was positive for 6/8 H. influenzae iso-
lates. Among the 2 beta-lactamase-negative H.
influenzae isolates, 1 was not tested against ampi-
cillin and the other was susceptible to ampicillin
(minimum inhibitory concentration [MIC]61 lg/mL).
4. Discussion
To the best of this studys knowledge, this is the
first study of AOM aetiology and antimicrobial sus-
ceptibility in Saudi children. Interestingly, among
the 66 AOM episodes included in this study, none
were recurrent and only 4 were reported in
children with antimicrobial treatment failure. The
observed number of AOM episodes peaked in
January 2010 and January 2011; this is consistent
with previous observations showing that AOM peaks
during the cold months as a consequence of
increased viral infections, which is an important
predisposition for the development of AOM [24].
In this study, the proportion of S. pneumoniae,
H. influenzae, M. catarrhalis and S. pyogenes iso-
lates (14/66) was lower than what has been
observed in other studies [25]. The number of H.
influenzae isolates was slightly higher than the
number of S. pneumoniae isolates, and no M.
catarrhalis or S. pyogenes isolates were detected.
The serotypes of the pneumococcal isolates were
7F, 23F, 19F and 15F, and all H. influenzae isolates
were NTHi. Besides the pathogens under study,
other bacteria were detected in 21/66 episodes,
and the most frequent isolate was S. aureus in
Saudi children with AOM. Although this bacterium
is an uncommon cause of AOM [26], a large propor-
tion of S. aureus-positive episodes observed in this
study suggests that it might become a more impor-
tant contributor to AOM following the introduction
of pneumococcal vaccines in the routine immunisa-
tion schedule. Further studies would be needed to
confirm this hypothesis, and the low yield of bacte-
rial cultures in this study does not provide any evi-
dence that the pathogen distribution in Saudi
Arabia differs from that observed in other
countries.
H. influenzae was identified in 4/11 episodes
reported in children who had been vaccinated with
a pneumococcal conjugate vaccine and in none ofthe unvaccinated children. Although the number
of children included in this study was too low and
the number of children with an unknown pneumo-
coccal vaccination status too high to draw any
relationship between vaccination and pathogen
distribution, these results are in line with those
of previous studies showing an increase of the
proportion of AOM episodes caused by NTHi after
the introduction of pneumococcal conjugate vac-
cines in immunisation programmes [4,27–29].
The first-line treatment for AOMgenerally recom-
mended by Saudi paediatricians varies, but the most
frequently prescribed antibiotics belong to the b-
lactam class, and more specifically to the cephalo-
sporin group (personal communication from Khalid
A. Al-Mazrou). Based on the breakpoints provided
by the Clinical and Laboratory Standards Institute,
the 6 S. pneumoniae isolates were susceptible to
cefotaxime, 5 to penicillin and 4 to cefuroxime,
and all H. influenzae isolates were susceptible to
both cefuroxime and cefotaxime [21].
This study was limited by the small number of
enrolled children (N = 66) compared with the num-
ber of screened children (N = 246), which may be
due to the facts that tympanocentesis is not prac-
ticed routinely in Saudi Arabia and many parents
refused the procedure to be done. Other limitations
of this study were the small number of isolates with
antimicrobial susceptibility results available and the
low culture-positivity rates, whichmay be explained
by the diagnostic criteria, by the previous use of
antibiotics or by viral aetiology. The use of molecu-
lar techniques, such as polymerase chain reaction,
and the analysis of nasopharyngeal swabs in addition
to the MEF samples could increase the number of
positive samples. A further limitation of this study
was the high proportion of children with an unknown
pneumococcal vaccination status, whichmay be due
to the facts that routine pneumococcal vaccination
was recently implemented in Saudi Arabia and par-
ents could not easily recognise the vaccines, or to
the fact that children in Saudi Arabia could be vacci-
nated at any healthcare facility and it was not possi-
ble to ask the parents to bring the vaccination card
before the visit.
5. Conclusions
In this study, 21% of AOM episodes recorded in
Saudi children were positive for either S. pneumo-
niae or NTHi. Although this study was limited by
the small sample size, these results confirmed that
these pathogens were major bacterial contributors
for AOM in young children. Beside these pathogens,
S. aureus, which is an uncommon cause of AOM,
Acute otitis media in Saudi children 237was detected in 26% of episodes, suggesting
that this bacterium might become an important
contributor to AOM following the introduction of
routine pneumococcal vaccination. Further studies
are needed to assess the burden and aetiology of
AOM, and the need to introduce additional vaccines
in the national immunisation schedule.
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